New study aims to help people with HIV quit smoking in south africa

NCT ID NCT05413122

Recruiting now Disease control Sponsor: Johns Hopkins University Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests two smoking cessation methods—varenicline pills and nicotine patches with gum—in 660 people with HIV in South Africa. Participants will receive one of these treatments for 12 weeks, along with counseling. The goal is to see which approach works best to help them quit smoking long-term, with follow-up at 26 and 52 weeks.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Varenicline and nicotine replacement therapy (patches and gum)
What this could lead to: If successful, this could provide an effective, scalable smoking cessation program integrated into HIV care, reducing smoking-related diseases in this population.
What could go wrong: This is a Phase 2/3 trial, so results are not yet proven. The interventions may not work as well in real-world settings, and side effects like nausea or skin irritation are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COMORBIDITIES AND COEXISTING CONDITIONS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

HIV infectious disease Smoking Cessation

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COMORBIDITIES AND COEXISTING CONDITIONS HIV SMOKING CESSATION

Contacts and locations

Locations

Perinatal HIV Research Unit (PHRU)
RECRUITING

Soweto, Gauteng, South Africa

More trials for these conditions

Other studies related to the condition(s) this trial covers.